[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100284932":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":36,"locations":44,"responsibleParty":64,"collaborators":18,"id":67,"slug":18,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":18,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":18,"overallStatus":47,"whyStopped":18,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Mississippi Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.",[13],"Drug: 17 OHPC",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","To determine how close the molecular markers are with 17 OHPC added to the management protocol.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","17 OHPC","The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.",[9],[26],"Study Drug",[28,32],{"name":29,"affiliation":30,"role":31},"Babbette LaMarca, PhD","University of Missisippi Medical Center","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":35},"Sheila S Belk","UMMC Pharmacology and Toxicology","STUDY_DIRECTOR",[37,41],{"name":29,"role":38,"phone":39,"phoneExt":18,"email":40},"CONTACT","(601)815-1430","bblamarca@umc.edu",{"name":42,"role":38,"phone":18,"phoneExt":18,"email":43},"Lorena M Amaral, Ph.D.","lmamaral@umc.edu",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Winfred L. Wiser Hospital","RECRUITING","Jackson","Mississippi","39216","United States",{"type":53,"coordinates":54},"Point",[55,56],-90.18481,32.29876,{"lat":56,"lon":55},[59,60],{"name":29,"role":38,"phone":39,"phoneExt":18,"email":40},{"name":61,"role":38,"phone":62,"phoneExt":18,"email":63},"Sheila Belk, MSCI","(601)984-1690","sbelk@umc.edu",{"type":31,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Babbette Lamarca","Chair and Professor, Pharmacology and Toxicology","100284932",false,"NCT02989025","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe\u002FSuperimposed Preeclampsia","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe\u002FSuperimposed Preeclampsia-The PROGRESS Pilot Study","PROGRESS","Inclusion Criteria:\n\n* UMMC antepartum patients with preterm PE between 23 0\u002F7ths and 34 0\u002F7ths weeks gestation when initially evaluated\n* Willing and able to understand study procedures and to provide informed consent\n\nExclusion Criteria:\n\n* \\>33 weeks gestational age or \\\u003C23 weeks gestation\n* Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC, pulmonary edema).\n* Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal heart rate decelerations, minimal to absent fetal heart rate variability).\n* Parameters according to current practice guidelines that exclude a patient from expectant management include the following:\n* Preterm premature rupture of membranes (PPROM) \\> 34 weeks gestation;\n* Platelet count \\\u003C 100,000\u002Fmicroliter (thrombocytopenia) with evidence of HELLP syndrome;\n* Persistently abnormal hepatic enzyme concentrations (twice or more upper normal values);\n* Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth percentile);\n* Severe Oligohydramnios (AFI \\\u003C 5cm)\n* Reversal of end diastolic flow(REDF) in umbilical artery Doppler testing;\n* Recurrent (\\> 2 readings \\> 30 minutes apart) severe hypertension despite antihypertensive therapy;\n* Eclampsia;\n* Pulmonary edema;\n* Abruption placentae;\n* Nonreassuring fetal status during daily testing (biophysical profile \\\u003C4\u002F10 and\u002For recurrent variable or late decelerations);\n* IUFD","FEMALE","18 Years","45 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.",[85,86],"Pregnancy","Preeclampsia (PE)","2026-04-27",{"date":89,"type":90},"2026-05-01","ACTUAL",{"date":92,"type":90},"2017-05-22",{"date":94,"type":79},"2027-01-31",{"name":5,"class":6},1]